logo

For the Inventor, By the Inventor

Gaithersburg, MD, United States of America

I-Mab Biopharma US Limited

USPTO Granted Patents = 14

% Expired Patents = 7.1



Forward Citations = 8

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Lei Fang (11 out of 39 patents)

silverMedal Bingshi Guo (10 out of 18 patents)

bronzeMedal Zhengyi Wang (10 out of 18 patents)

4.  Jingwu Zang (7 out of 17 patents)

5.  Wenqing Jiang (3 out of 8 patents)

6.  Feifei Cui (3 out of 3 patents)

7.  Haijuan Gu (3 out of 3 patents)

8.  Eunyoung Park (3 out of 8 patents)

9.  Eunsil Sung (3 out of 9 patents)

10.  Qiumei Yang (3 out of 5 patents)

11.  Byungje Sung (2 out of 9 patents)

12.  Yongqiang Wang (1 out of 20 patents)

13.  Wei Cao (1 out of 116 patents)

14.  Yuanyuan Yang (1 out of 3 patents)

15.  Weili Xu (1 out of 1 patent)


14 patents:

1. 12577313 - ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),
2. 12195538 - Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof (2025-01-14),
3. 12145982 - Anti-CXCL13 antibodies for treating autoimmune diseases and cancer (2024-11-19),
4. 12091467 - CD47 monoclonal antibodies and uses thereof (2024-09-17),
5. 11401331 - Anti-PD-L1 antibody and IL-7 fusions (2022-08-02),
6. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),
7. 11220546 - Anti-PD-L1 antibodies and uses thereof (2022-01-11),
8. 11208486 - Human PD-L1 antibodies (2021-12-28),
9. 11059897 - Anti-IFNAR1 antibodies for treating autoimmune diseases (2021-07-13),
10. 11034771 - Anti-CD73 anti-PD-L1 bispecific antibodies (2021-06-15),
11. 11028164 - Anti-CXCL13 antibodies (2021-06-08),
12. 10973853 - Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof (2021-04-13),
13. 10723799 - Anti-PD-L1 antibodies and uses thereof (2020-07-28),
14. 10584169 - Anti-CD73 antibodies and uses thereof (2020-03-10),
Company Overview
I-Mab Biopharma US Limited is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. With a strong emphasis on monoclonal antibodies and other biologics, the company leverages advanced research and technology to address unmet medical needs. Headquartered in Gaithersburg, Maryland, I-Mab is committed to advancing its pipeline of drug candidates through clinical development, aiming to bring transformative solutions to patients globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#35 in Gaithersburg, MD

#309 in Maryland

#22,333 in US

#42,290 in the World

Gaithersburg, MD (US)
Gaithersburg, MD, United States of America

I-Mab Biopharma US Limited

Forward Citations = 8

26 inventors:

goldMedal Lei Fang (11 out of 39 patents)

silverMedal Bingshi Guo (10 out of 18 patents)

bronzeMedal Zhengyi Wang (10 out of 18 patents)

4.  Jingwu Zang (7 out of 17 patents)

5.  Wenqing Jiang (3 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: I-Mab Biopharma US Limited. Retrieved from https://idiyas.com/company/i-mab-biopharma-us

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…